Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review

Fabiola Atzeni; Elisabetta Grillo; Ignazio F. Masala; Piercarlo Sarzi-Puttini; Gareth T. Jones

Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review

Fabiola Atzeni^*, Elisabetta Grillo, Ignazio F. Masala, Piercarlo Sarzi-Puttini, Gareth T. Jones

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

3 Citations (Scopus)

Abstract

Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.

Original language	English
Pages (from-to)	154-155
Number of pages	2
Journal	Israel medical association journal
Volume	18
Issue number	3-4
Publication status	Published - Mar 2016

Keywords

ankylosing spondylitis (AS)
psoriatic arthritis (PsA)
anti-tumor necrosis factor (TNF)
interstitial lung disease (ILD)
pulmonary fibrosis

Access to Document

http://www.ima.org.il/IMAJ/ViewArticle.aspx?aId=3849Licence: Unspecified

Cite this

@article{e9963b27577e4946807435acb18db9a2,

title = "Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review",

abstract = "Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.",

keywords = "ankylosing spondylitis (AS), psoriatic arthritis (PsA), anti-tumor necrosis factor (TNF), interstitial lung disease (ILD), pulmonary fibrosis",

author = "Fabiola Atzeni and Elisabetta Grillo and Masala, {Ignazio F.} and Piercarlo Sarzi-Puttini and Jones, {Gareth T.}",

year = "2016",

month = mar,

language = "English",

volume = "18",

pages = "154--155",

journal = "Israel medical association journal",

issn = "1565-1088",

publisher = "ISRAEL MEDICAL ASSOC JOURNAL",

number = "3-4",

}

TY - JOUR

T1 - Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review

AU - Atzeni, Fabiola

AU - Grillo, Elisabetta

AU - Masala, Ignazio F.

AU - Sarzi-Puttini, Piercarlo

AU - Jones, Gareth T.

PY - 2016/3

Y1 - 2016/3

N2 - Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.

AB - Lung involvement is a well-recognized extra-articular manifestation of ankylosing spondylitis (AS). Anecdotal reports suggest that the use of anti-TNF drugs may be related to lung disease and pulmonary fibrosis. To examine the association between anti-TNF drugs and the development of lung disease in patients with AS or psoriatic arthritis (PsA) we conducted a systematic review. Of the 670 papers identified by means of key word and hand search, only one full-text paper was considered potentially relevant but had to be discarded as it did not meet the eligibility criteria. Although no conclusion was reached, this is the first systematic review to examine this problem which is becoming increasingly important as these drugs are widely prescribed in patients with spondyloarthritis.

KW - ankylosing spondylitis (AS)

KW - psoriatic arthritis (PsA)

KW - anti-tumor necrosis factor (TNF)

KW - interstitial lung disease (ILD)

KW - pulmonary fibrosis

M3 - Literature review

SN - 1565-1088

VL - 18

SP - 154

EP - 155

JO - Israel medical association journal

JF - Israel medical association journal

IS - 3-4

ER -

Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review

Abstract

Keywords

Access to Document

Fingerprint

Cite this